N Lozovaya1, S Gataullina1, T Tsintsadze2, V Tsintsadze3, E Pallesi-Pocachard3, M Minlebaev4, N A Goriounova3, E Buhler3, F Watrin3, S Shityakov5, A J Becker6, A Bordey7, M Milh8, D Scavarda8, C Bulteau9, G Dorfmuller9, O Delalande10, A Represa3, C Cardoso3, O Dulac11, Y Ben-Ari3, N Burnashev3. 1. 1] INSERM U901, INMED, Parc Scientifique et Technologique de Luminy 163, route de Luminy-BP 13, 13273 Marseille Cedex 09, France [2] UMR901, Aix-Marseille University, 58 Boulevard Charles Livon, 13284 Marseille, France [3] INSERM U1129; University Paris Descartes, CEA, Gif sur Yvette, 149 Rue de Sèvres, 75015 Paris, France [4]. 2. 1] INSERM U901, INMED, Parc Scientifique et Technologique de Luminy 163, route de Luminy-BP 13, 13273 Marseille Cedex 09, France [2] UMR901, Aix-Marseille University, 58 Boulevard Charles Livon, 13284 Marseille, France [3]. 3. 1] INSERM U901, INMED, Parc Scientifique et Technologique de Luminy 163, route de Luminy-BP 13, 13273 Marseille Cedex 09, France [2] UMR901, Aix-Marseille University, 58 Boulevard Charles Livon, 13284 Marseille, France. 4. 1] INSERM U901, INMED, Parc Scientifique et Technologique de Luminy 163, route de Luminy-BP 13, 13273 Marseille Cedex 09, France [2] UMR901, Aix-Marseille University, 58 Boulevard Charles Livon, 13284 Marseille, France [3] Laboratory of Neurobiology, Kazan Federal University, Kremlevskaya street 18, 420000 Kazan, Russia. 5. Department of Anaesthesia and Critical Care, University of Würzburg, Josef-Schneider-Street 2, 97080 Würzburg, Germany. 6. Department of Neuropathology, University of Bonn Medical Center, Sigmund Freud Street 25, D-53105 Bonn, Germany. 7. Neurosurgery, and Cellular and Molecular Physiology Departments, Yale University School of Medicine, PO Box 208082, New Haven, Connecticut 06520-8082, USA. 8. APHM, Department of Pediatric Neurosurgery and Neurology, CHU Timone, 264 Rue Saint-Pierre, 13385 Marseille Cedex 5, France. 9. 1] INSERM U1129; University Paris Descartes, CEA, Gif sur Yvette, 149 Rue de Sèvres, 75015 Paris, France [2] Department of Pediatric Neurosurgery, Foundation Rothschild, 29 Rue Manin, 75019 Paris, France. 10. Department of Pediatric Neurosurgery, Foundation Rothschild, 29 Rue Manin, 75019 Paris, France. 11. 1] INSERM U1129; University Paris Descartes, CEA, Gif sur Yvette, 149 Rue de Sèvres, 75015 Paris, France [2] Department of Pediatric Neurosurgery, Foundation Rothschild, 29 Rue Manin, 75019 Paris, France [3] APHP, Necker Hospital, 149 Rue de Sèvres, 75015 Paris, France.
Abstract
Tuberous sclerosis complex (TSC), caused by dominant mutations in either TSC1 or TSC2 tumour suppressor genes is characterized by the presence of brain malformations, the cortical tubers that are thought to contribute to the generation of pharmacoresistant epilepsy. Here we report that tuberless heterozygote Tsc1(+/-) mice show functional upregulation of cortical GluN2C-containing N-methyl-D-aspartate receptors (NMDARs) in an mTOR-dependent manner and exhibit recurrent, unprovoked seizures during early postnatal life (<P19). Seizures are generated intracortically in the granular layer of the neocortex. Slow kinetics of aberrant GluN2C-mediated currents in spiny stellate cells promotes excessive temporal integration of persistent NMDAR-mediated recurrent excitation and seizure generation. Accordingly, specific GluN2C/D antagonists block seizures in Tsc1(+/-) mice in vivo and in vitro. Likewise, GluN2C expression is upregulated in TSC human surgical resections, and a GluN2C/D antagonist reduces paroxysmal hyperexcitability. Thus, GluN2C receptor constitutes a promising molecular target to treat epilepsy in TSC patients.
Tuberous sclerosis complex (TSC), caused by dominant mutations in either TSC1 or TSC2 tumour suppressor genes is characterized by the presence of brain malformations, the cortical tubers that are thought to contribute to the generation of pharmacoresistant epilepsy. Here we report that tuberless heterozygote Tsc1(+/-) mice show functional upregulation of cortical GluN2C-containing N-methyl-D-aspartate receptors (NMDARs) in an mTOR-dependent manner and exhibit recurrent, unprovoked seizures during early postnatal life (<P19). Seizures are generated intracortically in the granular layer of the neocortex. Slow kinetics of aberrant GluN2C-mediated currents in spiny stellate cells promotes excessive temporal integration of persistent NMDAR-mediated recurrent excitation and seizure generation. Accordingly, specific GluN2C/D antagonists block seizures in Tsc1(+/-) mice in vivo and in vitro. Likewise, GluN2C expression is upregulated in TSChuman surgical resections, and a GluN2C/D antagonist reduces paroxysmal hyperexcitability. Thus, GluN2C receptor constitutes a promising molecular target to treat epilepsy in TSCpatients.
Tuberous sclerosis complex (TSC) is an autosomal-dominant disease affecting multiple
organ systems (brain, skin, kidney, heart and lung) and caused by germline mutations in
one of the tumour suppressor genes, TSC1 or TSC2 (ref. 1). Inactivation of
either of these genes leads to hyperactivation of the mammalian target of rapamycin
(mTOR) pathway and promotes neuropathological abnormalities associated with TSC234. The most devastating clinical and pathological expressions of TSC
involves the central nervous system, and includes malformative brain lesions, the
cortical tubers, epilepsy, autism, cognitive impairment and glial tumours5. Epilepsy begins in infancy and is difficult to treat with 85–90% patients
remaining with pharmacoresistant seizures5.The molecular mechanisms governing epileptogenesis in TSC and the contribution of tuber
formation have been intensively studied during the last decade and were subjects of
intensive debates. Recent evidence indicates that gliomas are formed by biallelic
TSC1 or
TSC2 gene inactivation,
reflecting a double-hit mechanism according to which a germline or a somatic mutation
(likely occurring during development) affects the non-mutated allele, producing
‘loss of heterozygosity’6. However, loss of
heterozygosity at either TSC gene is a rare event in tubers in human7, and although it may affect selected population of giant cells within
cortical tubers, most of the cells in whole tuber sections have heterozygote
mutations8.Although correlations have been found between severity of the condition and the number of
tubers910, and between topography of cortical tubers and type of
epilepsy, it remains elusive whether tubers are intrinsically epileptogenic as some
patients with numerous tubers have a benign condition, whereas some others, without
tubers, have extremely severe epilepsy11121314. Furthermore, the
epileptogenic zone may not be exactly superimposed to the lesion and includes some
adjacent or, more rarely, remote areas12. This could explain why for
approximately one-third of individuals who undergo epilepsy surgery, seizures persist
after removal of the cortical tubers suspected to be epileptogenic910.
Thus, it is not clear what mechanisms underlie epilepsy in perituberal region and in
patients without evidence of cortical tubers or other dysgenetic features.Numerous animal models of TSC have been generated in order to evaluate the mechanisms by
which TSC genes loss results in the diverse pathological phenotypes. Mouse models
generated using different brain-specific promoters and conditional alleles, in which
both alleles of either Tsc1 or
Tsc2 are lost in
neurons or glia, display a severe neurological phenotype including morphological and
clinical TSC features such as tuber-like structures, failure to thrive, frequent
seizures and early mortality15161718. However, both heterozygous
Tsc1 and
Tsc2 knockout mice
demonstrate behavioural and electrophysiological abnormalities and cognitive dysfunction
in the absence of tubers or seizures41920. This supports the concept
that haploinsufficiency of Tsc1
or Tsc2 expression contributes
significantly to the brain manifestations of TSC, although epileptic phenotype has not
been reported so far for these mice.Possible mechanisms of seizure generation in TSC could include changes in excitatory and
inhibitory neurotransmitter function that may lead to abnormal neuronal synchronization
and imbalance between excitation and inhibition2122. Several reports
have shown an increased expression of excitatory amino-acid binding sites in the
epileptic cortex and altered ionotropic glutamate receptors expression patterns in human
cortical tubers23242526. N-methyl-D-aspartate
receptors (NMDARs) are putative candidates to explain the hyperexcitability of TSC
neuronal networks. Slow decay kinetics of the currents mediated by NMDARs could
facilitate synchronization in neuronal networks and thus exert proepileptic effects.
However, the functional and proepileptic significance of NMDARs in epileptogenesis
associated with TSC has not been explored.In this study, we report that heterozygote Tsc1mice show
functional upregulation of cortical GluN2C-containing NMDARs and exhibit spontaneous seizures associated
with clinical manifestations during early postnatal life (<P19) despite the
absence of major morphological changes in the brain1520. Selective
inhibition of these receptors strongly disrupts spontaneous epileptiform activity in
Tsc1mice. Furthermore,
electrophysiological and quantitative real-time reverse transcription polymerase chain
reaction (RT-PCR) analysis of postsurgical tissue from TSCpatients reveal upregulation
of GluN2C subunits, indicating that
these NMDAR subunits are instrumental in humanTSC. Collectively, these observations
suggest that an upregulation of GluN2C
subunits is of paramount importance in the manifestation of epileptic phenotypes
associated with TSC.
Results
Spontaneous seizures in Tsc1
mice
To characterize functional abnormalities of haploinsufficientTsc1mice, lacking
major malformations1520, in vivo intracortical
electroencephalography (EEG) recordings in somatosensory S1 cortex of
head-restrained non-anaesthetized Tsc1mice at
postnatal days P9–P33 were performed. Spontaneous recurrent seizures
occurred in 77% of Tsc1mice tested
at P9–P18 (26 out of 34), but were not observed in Tsc1mice of the same age (Fig. 1 and Supplementary Figs 1 and 2). The seizures
started 2–3 h after onset of EEG recordings and recurred
as often as six per hour. Ictal discharges were often associated with screaming,
oro-facial automatisms, head tremor, straub tail and tonic-clonic seizures (Supplementary Movie 1), followed by
a quiet behaviour (Supplementary Movie
2).
Figure 1
Spontaneous seizures in Tsc1
mice.
(a) Intracortical EEG recorded using a 16-channel silicone probe in a
head-restrained P16 Tsc1 mouse.
The upper channel corresponds to the superficial intracortical electrode
placed at 100 μm from the pia. Shown are epileptic
discharges recorded at the depths indicated on the left of each trace.
(b) Superimposed epileptic discharges in L4 of neocortex (red)
and hippocampus (black). (c) Wavelet analysis during the ictal events
for traces shown in b. Upper panel: neocortex, lower panel:
hippocampus. (d) Cumulative probabilities of seizures maximal
amplitudes for L2/3 and L4 (upper left, n=84 seizures, N=20
mice) and durations (upper right, n=104 seizures, N=20).
Seizure durations were the same for all layers, data for L2/3 are shown.
Bottom: relative integral power of
δ-(1–4 Hz),
θ-(4–8 Hz),
α-(8–12 Hz),
β-(12–25 Hz),
γ-(25–100 Hz) and fast ripple (FR;
100–500 Hz) band components of EEG in L2/3
(n=31 seizures, N=20) and L4 (n=29 seizures,
N=20) revealed by Fourier transform analysis. All
means±s.e.m.; *P<0.05, **P<0.01,
***P<0.001, two-sample two-tailed t-test.
Ictal EEG patterns started as high-frequency, low-amplitude activity that
progressively evolved to high-amplitude regular polyspike trains involving all
cortical layers. Subsequently, there were disruptions of the discharges with a
reduction in EEG amplitude in cortex and appearance of high-amplitude rhythmic
spike-wave trains in the hippocampus (Fig. 1a,b). Wavelet
analysis showed an increase in high-frequency activity during ictal discharges
(Fig. 1c). The contributions of δ,
γ and fast ripple bands in power spectrum during discharges were
significantly larger in neocortical layer 4 (L4) compared with layer 2/3 (L2/3;
Fig. 1d, bottom panels). The amplitude and duration of
discharges varied within litters with a mean amplitude of
615±18 μV and a mean duration of
70.3±5 s, (n=104 seizures; N=20 mice; Fig. 1d, upper panels). Interestingly, epileptic phenotype
was not observed in Tsc1mice at ages
older than P19 (P19–P33, N=10), indicating that this is a
developmental insult.The seizure onset as well as the peaks of averaged population spikes in L4
preceded those in L2/3 (Supplementary
Fig. 3a, mean delay for the peaks was 8.0±1.3 ms,
N=11 mice). These observations and current source density (CSD)
analysis suggest that epileptic activities in the cortex are initiated in
granular cortical layer before spreading to supra- and infragranular layers
(Supplementary Fig. 3b).Qualitatively, similar results were obtained in coronal slices of
Tsc1mouse
brains, where intralaminar circuitry and horizontal recurrent connections were
intact, but thalamo–cortical inputs were absent. In simultaneous
whole-cell recordings from somatosensory cortical excitatory neurons in L4 and
L2/3 spontaneous synchronized bursts were observed first in L4 and subsequently
in L2/3 neurons with an average delay of 30.4±5.5 ms (61
synchronous bursts were analysed; Fig. 2a,b). Therefore,
L4 neurons have a central role in neocortical epileptogenesis in
Tsc1mice.
Figure 2
Onset of spontaneous synchronous bursts in L4 preceded that in L2/3.
(a) Middle: traces of whole-cell currents recorded at
Vh=−70 mV simultaneously from
two PNs in L2/3 and two SSCs in L4 (shown schematically on the left) in
neocortical slices from Tsc1 mice.
Right: expanded traces of the same bursts marked by grey box are shown.
Vertical dotted line outlines bursts onset in L4. Note that onsets of the
bursts in L4 precede those in L2/3. (b) Distribution of the onset
delays (Δt) between bursts recorded simultaneously from
L2/3 and L4 neurons (61 synchronous bursts were analysed, N=4 mice).
Δt was measured from filtered (0.5 kHz)
events at the level of the burst threshold (Thr) set at 40 pA as
shown on the left. Events with amplitude <40 pA were not
considered as the bursts. Fitting a Gaussian Function of Δt
distribution revealed at least two peaks with the most of the
Δt values peaking at 12 ms.
Upregulation of GluN2B
and GluN2C/D NMDARs in
Tsc1
mice
L4 is the main collector of sensory information and cortical
‘hub’ for intracolumnal information processing27. Recurrent activity triggered within the highly interconnected
networks of L4 has been suggested to act to selectively amplify and redistribute
transient high-frequency thalamo–cortical inputs2829. What are the mechanisms underlying the increased integrative capacity of L4
neurons in Tsc1mice? As
NMDARs have an important role in L4 neuron integrative properties3031, we next examined whether slow NMDAR-mediated signalling was
altered in Tsc1mice.The L4–L4 connections are almost the only intracortical synaptic input
that L4 spiny stellate cells (SSCs) receive32. This allows an
estimation of the contribution of the slow NMDA component in isolated L4–L4 connections by
measuring spontaneous activity from SSCs. To monitor the NMDAR-mediated current,
we performed whole-cell recordings of spontaneous excitatory postsynaptic
currents (sEPSCs) from L4 SSCs (Fig. 3a) and L2/3
pyramidal neurons (PNs) in coronal brain slices from Tsc1mice
(P14–P16) in voltage-clamp mode at −50 mV. The
decay kinetics of the composite sEPSCs was significantly slower in
Tsc1 than that
in Tsc1mice both in L2/3 and L4
neurons (Fig. 3b,c), suggesting an increased contribution
of NMDAR-mediated current and an upregulation of GluN2B, and/or GluN2C and GluN2DNMDAR subunits endowed with slow
decay kinetics33. To quantify alterations in sEPSCs decay, we
measured charge transfer normalized by the peak amplitude (see Methods section
for details). In Tsc1mice,
normalized charges of sEPSC were 1.5±0.1 in L2/3 and 2.55±0.16
in L4 of those in Tsc1mice (L2/3: n=27
and 16 neurons; L4: n=34 and 29 neurons for Tsc1 and
Tsc1mice, respectively;
two-sample, two-tailed t-test Tsc1 versus Tsc1 in L2/3
P<5 × 10, and in
L4 P<1 × 10).
Bi-exponential-weighted time constants of sEPSC decay
(τw) were in Tsc1mice 7.5±0.6 ms for L2/3 and 7.4±0.4 ms
for L4, and in Tsc1mice
13.28±0.97 ms for L2/3 and 16.76±1.19 ms
for L4 (two-sample, two-tailed t-test Tsc1
versus Tsc1 in L2/3
P<2 × 10, and in
L4 P<8 × 10).
Corresponding amplitudes of sEPSC in Tsc1mice were
not significantly different from those in Tsc1mice in L4 (two-sample,
two-tailed t-test, P>0.7), however, they were slightly
increased in L2/3 (two-sample, two-tailed t-test, P<0.07;
Supplementary Fig. 4).
Figure 3
Layer-specific functional upregulation of GluN2B and GluN2C/D subunits containing NMDA receptors in
Tsc1
mice.
(a) Representative traces of spontaneous activity recorded in
whole-cell mode at holding potential −50 mV from SSCs
in L4 in neocortical coronal slices from Tsc1, Tsc1 mice
and in Tsc1 mice in
the presence of UBP141
(10 μM). (b) Grand averages of normalized
(Norm.) and superimposed traces of sEPSC recorded from PNs in L2/3 (left) or
SSCs in L4 (right) in Tsc1 and
Tsc1 mice at
−50 mV. For each neuron, original traces from
individual experiments were aligned based on the starts of their rising
phases and averaged. These averaged traces from individual experiments were
normalized and averaged to form grand average traces shown. Pooled data from
16 neurons for Tsc1 (N=5 mice) and
27 neurons for Tsc1 in L2/3
(N=8) and from 29 neurons for Tsc1 (N=6) and 34
neurons for Tsc1 in L4
(N=10). (c) Summary data for normalized charges of sEPSC
in L2/3 and L4 in Tsc1 and in Tsc1 mice
(relative to Tsc1). (d) Left
two panels: superimposed grand average of normalized traces of sEPSC
recorded in L4 in Tsc1 and Tsc1 mice in
control and in the presence of UBP141. Right two panels: superimposed grand average of
normalized traces of sEPSC recorded in L4 in Tsc1 and
Tsc1 mice pretreated
with either vehicle or rapamycin. (e,h) Summary data for the
effects of UBP141 and
Ro25-6981
(1 μM) on normalized charges of sEPSC (e) and
weighted time constant, τw (h) of sEPSC
decay in L2/3 in Tsc1 and in Tsc1 mice.
(f,i) Summary data for the effects of UBP141, DQP1105
(10 μM) and Ro25-6981 on normalized charges of sEPSC (f) and
τw (i) in L4 in Tsc1 and in Tsc1 mice.
(g,j) Summary data for the effects of UBP141 on normalized charges of
sEPSC (g) and τW (j) in L4 in
Tsc1 and in
Tsc1 mice
pretreated with either vehicle or rapamycin. All means±s.e.m. All data sets were
analysed using one-way ANOVA followed by Fisher’s Least
Significant Difference (LSD) post hoc test (see Supplementary Table 2 for statistics);
*P<0.05, **P<0.01, ***P<0.001.
NS, not significant,.
To directly determine the involvement of NMDAR subtypes in prolongation of
sEPSCs, we used specific GluN2B (Ro25-6981) and GluN2C/D (UBP141 (ref. 34), and
DQP1105 (ref. 35)) antagonists (Supplementary Table 1). In L4 SSCs in Tsc1miceUBP141 and DQP1105, but not Ro25-6981, accelerated sEPSCs decay,
restoring it to the values in Tsc1mice (Fig. 3d,f,i and Supplementary
Table 2), suggesting an increased contribution of GluN2C/D but not GluN2B subunits. In Tsc1mice, the
normalized charge of sEPSC in L4 in the presence of UBP141 (10 μM) was
0.61±0.07 (n=10, P<4 ×
10, paired two-tailed t-test)
and in the presence of DQP1105
(10 μM) was 0.48±0.04 (n=12,
P<2 × 10, paired
two-tailed t-test) of that without drugs. Relative
τw values were 0.56±0.06 for
UBP141 (P<5
× 10, paired two-tailed
t-test) and 0.41±0.04 for DQP1105 (P<3 ×
10, paired two-tailed t-test),
respectively, of those without drugs. In Tsc1mice, sEPSCs decay
kinetics was not affected by either drug (the normalized charge values were
similar in the presence and absence of the drugs: 1.03±0.13,
n=9, P>0.75 for UBP141 and 1.06±0.07, n=12,
P>0.4 for DQP1105; paired two-tailed t-test). Correspondingly,
the relative τw values were 0.98±0.07,
P>0.3 for UBP141 and 1.07±0.07, P>0.7 for
DQP1105 (paired two-tailed
t-test). Corresponding amplitudes of sEPSC for all sets were not
significantly different (analysis of variance (ANOVA), P>0.9; Supplementary Fig. 4).In addition, we performed recordings of miniature EPSCs (mEPSCs) in L4 cells in
the presence of tetrodotoxin
(1 μM). Similarly to sEPSCs, the average decay kinetics of
the late component in composite mEPSCs was significantly slower in
Tsc1 than that
in Tsc1mice (Supplementary Fig. 5). Thus, in
Tsc1mice,
averaged normalized charge of mEPSC in L4 was 2.58±0.18 of that in
Tsc1mice (n=10 and 9
neurons, for Tsc1 and
Tsc1mice, respectively;
two-sample, two-tailed t-test Tsc1 versus Tsc1
P<5 × 10). In
Tsc1mice, the
normalized charge of mEPSC and τw in L4 in the
presence of DQP1105
(10 μM) were 0.45±0.07 (n=8,
P<1.7 × 10, paired
two-tailed t-test) and 0.55±0.03 (n=9,
P<3.2 × 10, paired
two-tailed t-test), respectively of those without drugs. In
Tsc1mice, mEPSCs decay
kinetics were not affected by DQP1105: the normalized charge and τw
in the presence of DQP1105
were 0.96±0.14 (n=7, P>0.75, paired two-tailed
t-test) and 1.13±0.13 (n=8, P>0.48,
paired two-tailed t-test), respectively, of those without drug.
Corresponding amplitudes of mEPSC for all sets were not significantly different
(ANOVA, P>0.9; Supplementary Fig. 5).In contrast to the data in L4, the contribution of both GluN2B and GluN2C/D subunits was increased in L2/3
of Tsc1+/ mice. Both
Ro25-6981 and
UBP141 accelerated sEPSC
decay (Fig. 3e,h). In the presence of
1 μM Ro25-6981, the normalized sEPSC charge in Tsc1mice was
0.79±0.05 of control without Ro25-6981 (n=9, P<0.005, paired
two-tailed t-test). In Tsc1mice, this value was
1.03±0.09 (n=6, P>0.75, paired two-tailed
t-test). Similarly, corresponding numbers for UBP141 in L2/3 were 0.8±0.07
of controls without the drug (n=12, P<0.02, paired
two-tailed t-test) in Tsc1+/ mice and
1.02±0.07 (n=9, P>0.8, paired two-tailed
t-test) in Tsc1mice. However, the
interpretation of UBP141
effects in L2/3 is complicated by the fact that at a concentration of
10 μM it partially affects also GluN2B receptors (Supplementary Table 1). The amplitudes of
sEPSCs in the presence of antagonists were not significantly different from
control values for all experimental sets (ANOVA, P>0.15; Supplementary Fig. 4).Therefore, there is an increased contribution of GluN2C/D subunits in L4, but of both
GluN2B and GluN2C/D subunits in L2/3 in
Tsc1+/ mice when
compared with naive Tsc1wt mice.To determine whether upregulation of the GluN2C/D-NMDAR component in L4 is a direct consequence of
enhanced mTOR signalling caused by Tsc1 inactivation, we performed experiments in
Tsc1mice
chronically treated with the mTOR inhibitor rapamycin (see Methods section).
Recordings of sEPSC from SSCs in L4 in rapamycin-treated Tsc1mice
(P14–P16) showed the absence of the UBP141-sensitive component (Fig. 3d,g,j). In rapamycin-treated Tsc1mice, the
normalized charge of sEPSCs in SSCs in the presence of UBP141 (10 μM) was
1.05±0.11 (n=12, P>0,6, paired two-tailed
t-test) of that without the drug. Furthermore, normalized charge of
sEPSCs in rapamycin-treated
Tsc1mice was
not significantly different from that of vehicle-treated Tsc1wt mice
(1.05±0.08 of that in vehicle-treated Tsc1mice, n=14 for Tsc1, n=10
for Tsc1, two-sample two-tailed
t-test P>0.75; Fig. 3g). This
finding indicates a crucial role of mTOR signalling in functional upregulation
of GluN2C/D-containing NMDARs
in Tsc1mice.Interestingly, in L4 fast-spiking (FS) interneurons neither UBP141 nor Ro25-6981 altered sEPSCs decay in both
Tsc1wt and Tsc1mice (Supplementary Fig. 6), suggesting
that NMDAR-mediated currents in inhibitory neurons remain intact.To further determine the functional effects of UBP141 in Tsc1mice, we
tested its actions on the amplitude and frequency of
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPAR)-mediated sEPSCs. UBP141 altered neither the amplitude nor the kinetics of
AMPAR-mediated sEPCS recorded at −80 mV in L4 SSCs (Supplementary Fig. 7a,b). The
frequency of sEPSCs recorded at −80 mV in L4 SSCs was not
different from that in Tsc1mice. However, in L2/3
PNs it was significantly higher than that of Tsc1mice (Supplementary Fig. 7c), and
was reduced by bath application of UBP141 in Tsc1 (Supplementary Fig. 7e), but not in
Tsc1 (Supplementary Fig. 7d) mice. Therefore, in
Tsc1mice L4
GluN2B/C/D channels
presynaptic to L2/3 PN could contribute to increase the activity of the
latter.mTOR-dependent upregulation of the slow NMDAR subunits was confirmed by
quantitative RT–PCR revealing 2.4-fold elevation of GluN2C mRNAs (P<0.005,
two-tailed t-test) in the neocortex of Tsc1mice
(N=5) compared with age-matched Tsc1
(N=5) mice (Supplementary Fig.
8).Thus, the contribution of GluN2C-containing NMDARs with slow kinetics is increased in
neocortical L4 and L2/3 excitatory neurons in mice with haploinsufficientTsc1 mutation.
Similar alterations in sEPSC kinetics were observed in
‘double-hit’ Tsc1 mutant mice. In a recent study, using in
utero electroporation and relying on the «second-hit»
mutation concept36, Bordey and co-workers15
generated a Tsc1
animal model with the hallmark of humanTSC, namely the tubers. We used this
model to test the impact of a «second-hit» mutation on
functional upregulation of slow NMDARs. To do that, Tsc1mice (as well as
Tsc1) were injected
in utero at embryonic day 16 (E16) with pCAG-mRFP alone or combined
with pCAG-Cre:GFP to induce, after electroporation, deletion of the floxed
Tsc1 gene in a
subset of neurons. The fluorescence of the monomeric red fluorescent protein
(mRFP) plasmid allows identification of electroporated neurons and green
fluorescent protein (GFP) for detection of neurons containing pCAG-Cre.
Whole-cell recordings in neocortical slices from
mRFP+/GFP+ neurons of Tsc1; pCAG-Cre and
Tsc1; pCAG-Cre
conditional knockout mice (hereafter referred to as Tsc1
and Tsc1 neurons,
respectively) at −50 mV revealed enhanced contribution of
slow UBP141-sensitive
NMDAR-mediated components in sEPSC compared with those from control
mRFP+ neurons of Tsc1mice, in the same
manner as in non-electroporated heterozygote Tsc1mice.
Therefore, GluN2C/D-mediated
currents are present in both Tsc1 and
«double-hit» Tsc1 neurons. Importantly,
the extent of slow NMDARs contribution was the same for the electroporated
neurons with heterozygote and homozygote Tsc1 mutations (Supplementary Fig. 9).
Slow NMDAR-mediated signal determines temporal integration
To test temporal summation at γ-band frequency, we performed
simultaneous whole-cell recordings from pairs of synaptically coupled SSCs in L4
of somatosensory cortex in slices from Tsc1 and
Tsc1P14–P16mice. The majority of interconnected excitatory neurons were SSCs with an
asymmetrical dendritic arborization largely confined to L4 and characteristics
action potentials firing pattern (Fig. 4a,b). In
concordance with the slower NMDAR-mediated component of synaptic transmission in
Tsc1mice,
recordings revealed a significantly higher extent of temporal integration
compared with Tsc1mice when measuring
EPSCs evoked by stimulation of presynaptic cells with a train of action
potentials. Normalized charge transfer of the train-EPSCs estimated from
normalized by the amplitude of the first peak currents was
0.093±0.004 s in Tsc1
(n=5) and 0.050±0.006 s (n=7) in
Tsc1mice, respectively,
(P<0.0005, two-tailed t-test; Fig.
4c–e). Furthermore, recordings in Tsc1mice
demonstrated significantly increased contribution of UBP141-sensitive NMDAR-mediated
train-EPSCs to the postsynaptic summation of EPSCs but not in Tsc1mice (Fig. 4d,f,g). In the presence of UBP141, the normalized sEPSC charge in
Tsc1mice was
0.57±0.11 of that without UBP141 (n=4, P<0.03, paired two-tailed
t-test). In Tsc1mice, this value was
1.06±0.07 (n=6, P>0.44, paired two-tailed
t-test). Thus, abnormal slowing of the NMDAR-mediated current kinetics
increases temporal integration within recurrent network in L4 of
Tsc1mice.
Figure 4
Enhanced temporal integration of synaptic responses in synaptically coupled
SSCs in L4 in Tsc1
mice.
(a) Fluorescence images from two SSCs (left) and the configuration of
a paired recordings (right). Scale bar, 50 μm.
(b) Representative action potential firing patterns of both,
postsynaptic (top) and presynaptic (bottom) SSCs recorded in current clamp
mode. (c,d) Representative averaged normalized by the first
peaks in the trains traces of EPSCs recorded in voltage-clamp mode in pairs
of SSCs in L4 (averaged 25 sweeps) from Tsc1 (c, bottom
panels) and Tsc1
(d) mice induced by train stimulation (11 stimuli at
40 Hz) in presynaptic cell in the absence (left panels, black
traces) or presence (middle panels, red traces) of UBP141
(10 μM). Top traces in c represent averaged
superimposed presynaptic SSC action potentials in control and in the
presence of UBP141. Right
panels: the traces in the absence and in the presence of UBP141 are superimposed. (e)
Normalized charge transfer of the train-EPSCs estimated from normalized by
amplitude of the first peak currents is increased in Tsc1
(n=5 cell pairs, N=4 mice) compared with Tsc1 mice (n=7 cell
pairs, N=4), P<0.0005, two-tailed t-test.
(f) UBP141
decreases the contribution of NMDAR-mediated EPSCs to the postsynaptic
summation of EPSCs in synaptically coupled SSCs in Tsc1 mice.
Normalized charge transfer of the train-EPSCs from Tsc1 mice in
control (n=5 cell pairs, N=4), in the presence (n=4
cell pairs, N=4) and after washout of UBP141 (n=3 cell pairs,
N=3). Tsc1 versus
Tsc1 in the
presence of UBP141,
P<0.03, two-tailed t-test). (g) Normalized
charge transfer of the train-EPSCs is unaltered in the presence of
UBP141 in
Tsc1 mice (n=6
cell pairs, P>0.44, two-tailed t-test). All
means±s.e.m., *P<0.05, ***P<0.001. NS,
not significant.
GluN2C/D antagonists
reduce epileptogenecity in Tsc1
mice
The critical role of L4 neurons in increased temporal integration and seizure
generation suggests that the selective blockade of long-lasting GluN2C/D subunits containing
NMDAR-mediated currents may have antiepileptic effects. To test this
possibility, we first used microelectrode array extracellular recordings in
acute coronal neocortical slices taken from P15Tsc1mice.
Spontaneous discharges lasting for up to 10 s were recorded in L2/3
and L4. UBP141
(10 μM) selectively reduced the amount of long-lasting
epileptiform episodes, without altering the number of interictal bursts
(duration≤500 ms; Supplementary Fig. 10).We next tested the antiepileptic actions of UBP141 and DQP1105
in vivo by intraperitoneal (i.p.) injections of the drugs (75 and
28 mg kg,
respectively) to Tsc1mice. These
values were the lowest effective doses identified by testing increasing doses of
these compounds (see Methods section for details). In three of six mice tested,
the seizures were completely stopped ~40 min after i.p.
injection of UBP141, and in
the remaining mice (n=3) there was a seizure-free period lasting
109±39 min (Fig. 5a,b). I.p. injection
of DQP1105 stopped seizures
on average for 72.6±5.5 min in four out of six mice, and
seizures were completely stopped in two mice (Fig. 5c). In
contrast, recurrent epileptic discharges persisted up to 7 h in
Tsc1mice that
did not receive the antagonists or were i.p. injected with vehicle (Fig. 5d,e). Therefore, selective antagonists of
GluN2C/D-containing
receptors have in vivo and in vitro antiepileptic actions in
Tsc1mice.
Figure 5
Acute antiepileptic effect of i.p. administration of UBP141 or DQP1105
in vivo.
(a) Intracortical EEG recordings in head-restrained P15
Tsc1 mouse
before and after i.p. administration of UBP141
(75 mg kg;
indicated by arrow). The upper trace corresponds to the superficial
intracortical electrode placed at 100 μM from the pia,
channels are separated by 200 μm.
(b–e) Time course of spontaneous seizure
activity in Tsc1 mice at
P14–P16 before and after i.p. administration of UBP141 (N=6 mice; b),
DQP1105
(28 mg kg,
N=6; c), vehicle control (N=3; d) and
control without any treatment (N=3; e). Individual seizures
are represented by black squares. Each row (#) represents individual
experiment.
Importantly, after UBP141
injection a basal activity remained unaltered, in particular, at
γ-frequency band (Supplementary
Fig. 11), known to be enhanced by common NMDAR antagonists37. This might indicate that used dosage of UBP141 corresponds to the concentration
in the brain to be within the selectivity range for GluN2C/D. The used dosage of
DQP1105
(28 mg kg)
according to in silico prediction tools appears to be also within the
selectivity range for GluN2C/D receptors (see Methods section for details and Supplementary Table 1). The direct
assessment of the distribution of both drugs in the brain requires further
studies.Collectively, our observations on the Tsc1 animal
model suggest that seizures are generated intracortically owing to an
upregulation of GluN2C
receptors in recurrent connections between SSCs in the granular layer of
neocortex and then propagate to other layers. Interestingly, in some
Tsc1mice
sensory stimulation (mainly back and feet corresponding to receptive field in
the recorded cortical zone) induced a seizure (Supplementary Fig. 12), indicating that
sensory inputs to L4 may trigger paroxysmal recurrent network activity in the
cortex. This strongly reinforces the importance of the hyper-synchronizing
effects of L4 and of functional upregulation of GluN2C subunits of NMDARs.
GluN2C overexpression
in human TSC postsurgical tissue
To test whether findings obtained in the animal model can be translated to humanpatients with TSC, we performed studies in human postsurgical tissue.
Quantitative RT–PCR performed in human samples with TSC2 mutation (age at surgery
ranged from 8 to 16 months; Supplementary
Table 3) revealed a 20-fold increase of GluN2C mRNA compared with fetal control
brains (Fig. 6a; P<0.001, two-tailed
t-test) and more than 2.5-fold increase compared with adult control
brains.
Figure 6
Upregulation of GluN2C
subunit of NMDARs in human postsurgical tissue of TSC patients.
(a) Differential expression of NMDA receptor subunits in human brain
tissue from normal individuals and TSC patients. Left panel: quantitative
RT-PCR showing the relative expression of mRNAs encoding different NMDAR
subunits in normal samples from human fetal (pool of 59 male/female
Caucasian fetuses ages 20–33 weeks) and adult (pool of 10
male/female Caucasians ages 20–68 years) cerebral cortex. The
error bars indicate ±s.e.m. from two replicates of quantitative
RT-PCR experiments for both sets. β-actin and GAPDH were used for
normalization. Right panel: fold change expressions for each receptor in two
TSC patients calculated relative to the normal fetal brain. The error bars
for patient 1 indicate the ±s.e.m. from two replicates of
quantitative RT-PCR experiments. The error bars for patient 2 indicate the
±s.e.m. from three samples. All samples were tested in duplicate.
(b) Morphology of dysplastic excitatory neurons in cortical
slices of human postsurgical tissue of TSC patients. Scale bar,
50 μm applies to both images. (c) Grand averages
of normalized (Norm.) and superimposed traces of sEPSC recorded at
−50 mV from dysplastic neurons in cortical slices of
human postsurgical tissue of three TSC patients in control (pooled data from
eight neurons) and in the presence of 10 μM
UBP141 (pooled data
from seven neurons). (d) Summary data for the effects of
10 μM UBP141 on amplitudes, normalized and total charges of
the sEPSC recorded from human postsurgical tissue (relative to corresponding
controls, n=7 cells). All means±s.e.m.,
*P<0.05, **P<0.01; paired two-tailed
t-tests.
Whole-cell patch-clamp recordings in brain slices from the humanTSC specimens
showed that sEPSCs recorded from dysplastic neurons in granular and
supragranular layers (Fig. 6b) were significantly reduced
and curtailed by UBP141
(Fig. 6c,d). The amplitude, total and normalized
charges of sEPSC in the presence of UBP141 (10 μM) were 0.78±0.04
(P<0.002, paired two-tailed t-test, n=7),
0.59±0.08 (P<0.002, paired two-tailed t-test,
n=7) and 0.68±0.09 (P<0.01, paired two-tailed
t-test, n=7), respectively, of controls. The values of
τw of sEPSC decay in TSC samples were
16.6±2.1 ms without UBP141 and 8.69±0.71 ms in the presence
of UBP141
(P<0.0002, two-samples two-tailed t-test, n=7).Furthermore, in two human tissue samples displaying spontaneous paroxysmal
activity UBP141
(10 μM) reduced spontaneous spike frequency (Supplementary Fig. 13). Therefore, in
conjunction with animal model data functional upregulation of GluN2C may contribute to epilepsy
associated with TSC in humanpatients.Genetic polymorphisms and biochemical markers of mTOR activation have been also
identified in patients with isolated focal cortical dysplasia (FCD), a common
aetiology of intractable epilepsy3839404142.
GluN2B and GluN2C mRNA levels have been found to
be upregulated in dysplastic neurons microdissected from humanFCD specimens
obtained during epilepsy surgery26. Therefore, we tested whether
slow UBP141-sensitive
NMDAR-mediated component is present in dysplastic neurons from patients with
FCD. Whole-cell patch-clamp recordings were performed in five human samples (age
at surgery ranged from 1 to 14 years; Supplementary Table 4). As in the TSC case, sEPSCs recorded from
dysplastic neurons in granular and supragranular layers (Fig.
7a) were significantly curtailed by UBP141 (Fig.
7b,c). The τw values of sEPSC decay were
22.7±2.9 ms in control (n=17) and
9.9±0.7 ms in the presence of UBP141 (n=13,
P<0.001, two-sample, two-tailed t-test). The total and
normalized charge of sEPSC in the presence of UBP141 (10 μM)
were 0.56±0.08 (P<0.0003, paired t-test,
n=12) and 0.59±0.06 (P<2 ×
10, paired two-tailed-test,
n=12) of controls, respectively. Amplitudes of sEPSC in the presence of
antagonists were not significantly different from control: 0.88±0.07 of
control (P>0.16, two-tailed t-test; Fig.
7d).
Figure 7
Functional upregulation of GluN2C/D subunits of NMDARs in pediatric epilepsy surgery
patients with focal cortical dysplasia (FCD).
(a) Morphology of dysplastic excitatory neuron in cortical slice of
human postsurgical tissue of a patient with FCD. Scale bar,
50 μm. (b) Grand average traces of sEPSC
recorded at −50 mV from dysplastic neurons in cortical
slices of human postsurgical tissue of five patients with FCD in the absence
(red, pooled data from 17 neurons) and in the presence of
10 μM UBP141 (blue, pooled data from 12 neurons). (Green
trace)—UBP141-sensitive sEPSC component revealed by subtraction
of the trace with UBP141
from the trace without UBP141. (c) Grand average traces of sEPSCs
normalized (Norm.) by peak amplitudes. (d) Summary data for the
effects of 10 μM UBP141 on amplitudes, normalized and total charges of
the sEPSC recorded from human postsurgical tissue relative to corresponding
controls. All means±s.e.m., **P<0.01,
***P<0.001.Two-sample t-tests were performed on the
pooled data for each parameter (control conditions: n=17 cells, with
UBP141: n=12
cells). NS, not significant.
Thus, although our direct results are designed for studying the mechanisms of
epileptogenesis associated with TSC1 mutation, they may provide important link for other
neurodevelopmental disorders with epilepsy associated with mTOR activation such
as FCD.
Discussion
Our observations provide the first evidence that GluN2C NMDARs are functionally upregulated in neurons of
heterozygote Tsc1mice and in
humanTSCpatients. The upregulated expression of GluN2C receptors in neocortical L4 appear
as prerequisite for seizure generation in the developing haploinsufficientTsc1+/ mice despite
the absence of tubers and are key factors in the mechanisms of intracortical
epileptogenesis. In line with this concept, GluN2C/D receptor antagonists stop seizures in vivo and
in vitro. Our data with rapamycin-treated mice indicate a crucial role of mTOR
signalling in increased functional expression of GluN2C NMDARs in Tsc1mice. Finally,
examination of postsurgical tissue samples from TSCpatients revealed that these
findings could be potentially translated to human. Overall, our data suggest that
GluN2C-subunit targeted
therapy provides a promising novel therapeutic avenue to treat epilepsy associated
with TSC.Our in vivo recordings show that Tsc1mice exhibit a
variety of seizure types (most often generalized, up to 7 min duration).
Fast Fourier transform power spectra analysis of the EEG recordings revealed
increased contribution of fast and ultrafast (200–500 Hz)
oscillations—an important hallmark of epileptiform activity. EEG patterns
in Tsc1mice resemble
those seen in humanepileptic seizures, and are typically associated with remarkable
behavioural phenotype: freezing, facial automatisms, head tremor, straub tail and
tonic-clonic seizures. Seizures in this animal model, therefore, entirely fulfil the
criteria and definition of epileptic seizures proposed by the International League
Against Epilepsy and the International Bureau for Epilepsy43.However, some features and clinical phenotype in this animal model are distinctive
from the human disease: in particular in miceseizures spontaneously disappear after
P19, whereas in children with TSCseizures are usually highly persistent, although
seizure type may change with age.Both Tsc1 and
Tsc2 heterozygous
knockout mice have been intensively studied in the last years. Tsc1 and
Tsc2mice show
social and cognitive deficits in the absence of any apparent major cerebral
pathology41920, although loss of a single copy of Tsc
gene is sufficient to perturb neuronal morphology, dendritic spine structure22 and axon guidance44. Eventually, it has been proposed
as a model in which haploinsufficiency for the Tsc genes leads to aberration
in neuronal functioning, including changes in synaptic strength and glutamate
receptor composition of excitatory synapses, resulting in impaired learning and
social behaviour. Importantly, the mTOR complex 1 (mTORC1) inhibitor rapamycin improves learning and memory
deficits in Tsc2 mice4, and social deficit in both Tsc1 and
Tsc2mice,
suggesting that uncontrolled mTORC1 signalling is a core molecular mechanism
involved in the behavioural abnormalities1945.Thus, although micehaploinsufficient for the Tsc genes have been utilized as
models of autism41920, occurrence of spontaneous seizures in
Tsc1 and
Tsc2 rodents have
not been reported previously46. It is possible that early spontaneous
epileptic activity in Tsc1 heterozygous
knockout mice has been overlooked because of the strictly limited age window
(<P19) found in our study. Interestingly, in 82.1% of epilepticTSCpatients,
the epilepsy begins before 3 years of life47. Thus, this early
seizure appearance in Tsc1mice is
consistent with the early epilepsy onset in TSCpatients.Spontaneous seizure discharges in Tsc1mice involve
neocortical L4 before supra- and infragranular layers, both in vivo and in
vitro, indicating layer L4 as a possible origin of seizure generation. L4 is
the main acceptor of sensory inputs in which SSCs act as effective integrators of
powerful and persistent NMDAR-mediated recurrent excitation2931. On
the other hand, L4 neurons provide synaptic outputs to virtually all layers in a
cortical column (for review, see ref. 27). We suggest
that in Tsc1mice, L4 SSCs
with functionally upregulated GluN2C receptors become effective
‘hyperintegrators’ of powerful recurrent excitation and
intracortical epileptic generator. It has been hypothesized that normal brain
circuits provide a template that epileptic brain uses to generate seizures48, and in particular that circuits responsible for generating seizure
activity are comparable to the circuits that generate spindle bursts49. The rhythmic spike-wave discharge has been referred to as a perversion of the
spindle oscillation50 with the circuits within the cortex amplifying
the spindle activity. This hypothesis was derived primarily from CSD analysis of
cortical region during spindle activity51, showing that early
significant current sink occurs in cortical L4. This is in line with our own
observations. Intriguingly, tactile stimulation of the Tsc1mouse back induced
prominent seizures (Supplementary Fig.
12), indicating that seizure initiation can be triggered by conventional
sensory inputs to L4.Extensive recurrent connectivity due to upregulated GluN2C receptors in granular layer provide
a source of powerful local excitation and is capable of producing activity that is
self-generated and long-lasting. Rhythmic activity in the EEG γ-band is a
near-ubiquitous feature of ongoing cortical activity and responses to sensory input,
and this activity has been found selectively enhanced in epilepsy52.
Combined computational and experimental approaches show that high-frequency
γ rhythms originate particularly from L4 (ref. 53)53. Our
data show that slow decay of the GluN2C-mediated current contributes more efficiently to temporal
summation at high-frequency activity. Indeed, direct paired recordings of recurrent
connections between SSCs in L4 revealed increased temporal integration of excitatory
input in Tsc1mice at
γ-band frequency synaptic input. As a result neurons become more
depolarized for a longer time window promoting neuronal hypersynchronization within
L4. In concordance with patch-clamp data, i.p. injection of GluN2C/D antagonists stopped recurrent
seizures in Tsc1mice in
vivo.Intriguingly, the impact of «second-hit» mutation on functional
upregulation of slow NMDARs in neurons was negligible. Precisely, controlling the
timing and location of Cre expression, we could compare the cell-autonomous
effects of loss of Tsc1 in
an otherwise unperturbed circuit or loss of both alleles in heterozygous background
in contrast to the mouse models where Tsc1 is deleted in all forebrain neurons. The results
showed that extent of slow NMDAR receptor contribution was the same irrespectively
whether neurons were heterozygote or homozygote for the Tsc1 mutation. This indicates that
monoallelic mutation in the Tsc1 gene is sufficient to increase the functional
expression of GluN2C
receptors.Altered expression NMDAR mRNA has been reported for both humanTSC and FCD2426. In particular increased levels of GluN2B and GluN2D subunits mRNA were observed in
tubers24. These data differ from present data where selective
upregulation of GluN2C was
observed. This discrepancy might be attributed to the difference in methods used and
different age group of patients: 1-year-old patients in our study and
4–46-year-old (on average 19.5±6 years) patients in ref.
24. However, selective upregulation of
GluN2C-subunit mRNA in single
microdissected dysplastic neurons (shown in ref. 24) is
in a good agreement with functional upregulation of GluN2C/D subunits shown by our
electrophysiological data in individual dysplastic neurons. Importantly, sEPSCs
recorded from dysplastic neurons brain slices resected from patients with TSC and
FCD were significantly attenuated and curtailed by GluN2C/D antagonists. Thus, given an
increased expression of specific NMDAR subunits found in tissue resected from
patients with various types of drug-resistant epilepsy25265455,
the proposed mechanisms of intracortical epileptogenesis and NMDAR-subunit targeted
therapy may be further extended to other types of epilepsy, including FCD, the most
frequent congenital lesions causing epilepsy.It should be noted, however, that studies on postsurgery samples from TSC and FCDpatients need to be interpreted with some caution. This includes our comparative
findings from paediatric tissue from TSCpatients (~1-year old) with
normal fetal tissue. Non-epileptic normal age-matched control tissue is not
available for this human study owing to ethical issues, while comparison with
age-matched epileptic tissue with different aetiology may lead to misinterpretation
and wrong conclusions. Our results should be replicated in other clinical studies
with larger cohorts and rigorous age correlation analysis.The failure of general NMDAR antagonists to treat epilepsy in preclinical
studies56 may result from the need to restrict the NMDARs
blockade to the specific subunits involved in epileptogenesis in TSC leaving intact
pro-survival GluN2A-mediated
signalling involved in normal development, plasticity, learning and memory57. Administration of non-specific NMDAR antagonists alters γ
rhythms and can induce cognitive as well as psychosis-like symptoms in humans58. In FS parvalbumin-positive interneurons, NMDARs have a critical
role for expression of normal γ rhythms and specific cognitive
behaviours59. The disruption of NMDAR signalling specifically in
parvalbumin-positive interneurons may lead to neural network dysfunction that could
underlie these symptoms. The NMDARs present in FS interneurons, both in
Tsc1 and Tsc1mice, were not
affected by selective GluN2B or
GluN2C/D antagonists in our
experiments. This suggests that treatment with these compounds does not alter
inhibition provided by FS interneurons. Furthermore, power of γ
oscillations of basal activity recorded in Tsc1mice in
vivo was not affected by UBP141.Abnormal signalling in the mTOR pathway is known to be critical for the
pathophysiology of epilepsy and other neurological features of TSC, and other focal
cortical malformations. In animal models of TSC and cortical dysplasia,
hyperactivation of the mTOR pathway promotes epileptogenesis and neuropathological
abnormalities, and the mTOR inhibitor, rapamycin, prevents epilepsy and associated cellular and
molecular phenotypes23460. Altered mTOR pathway signalling was
found in TSC, FCD, hemimegalencephaly and ganglioglioma brain tissue specimens3840616263. The term ‘TORopathies’ was
recently coined to define a continuum of neurological disorders characterized by
altered cortical architecture, abnormal neuronal morphology and intractable seizures
as a consequence of abnormal mTOR signalling6364. There is strong
evidence supporting a role for mTORC1 in regulating the translation of a number of
proteins necessary for synaptic plasticity65, and there is a
possibility that mTORC1 also regulates translation of GluN2C. Our findings obtained from TSC
animal model may, therefore, also have implications for other conditions in which
mTORC1 is hyperactive, ranging from Fragile X syndrome to autism spectrum
disorders66.
Methods
Animals
Breeding and experimental procedures were carried out in accordance with European
guidelines for animal research and in accordance with Institut National de la
Santé et de la Recherche Medicale guidelines for animal care in
research, and were approved by the local ethics committee (Comité
d’éthique en expérimentation animale de Marseille
(C2EA-14)). Heterozygote Tsc1 (Tsc1, National
Cancer Institute (NCI, USA)) male mice were kindly provided by Dr A. Bordey
(Yale University, USA), and Tsc1 were obtained from
Jackson Laboratories. The genetic background of Tsc1mice was B6;129S4 and
Tsc1mice were from a
mixed background (C57BL/6J, BALB/cJ, or 129/SvJae mice). These lines of mice
were generated by David J. Kwiatkowski (Brigham and Women’s Hospital,
Harvard Medical School, Cambridge, MA, USA). Inbred C57BL/6J wild-type
(Tsc1) females were from
Janvier Labs (France). Mice were housed in ventilated, light-tight,
sound-isolated chambers under standard 12:12 light/dark cycle (light on at 07.00
PM and light off at 07.00 AM) with food and water available ad libitum.
Genotyping of pups issued from breading of C57BL/6J Tsc1 males and
C57BL/6J Tsc1+/+ females mice was performed on
tail tissue samples at postnatal days P11–P12. The study was
conducted in Tsc1 and
Tsc1mice of both sexes
issued from the same litters at P9–P33.
In utero electroporation
Timed pregnant female mice at the E16 (E0 is counted as the morning on which the
vaginal plug is detected) were anaesthetized with a mixture of ketamine
(10 mg kg)/xylazine
(100 mg kg).
The uterine horns were exposed, and a lateral ventricle of each embryo was
injected using pulled glass capillaries and a microinjector (Picospritzer II; General
Valve) with Fast
Green
(2 mg ml;
Sigma, USA) combined with the following DNA constructs:
0.5 mg ml
pCAG-mRFP either alone or with
1.5 mg ml
pCAG-Cre:GFP. Plasmids were further electroporated by discharging a 4,000-mF
capacitor charged to 35 V with a BTX
ECM 830 electroporator (BTX Harvard
Apparatus). The voltage was discharged in five electrical pulses
at 950-ms intervals via 5-mm electrodes placed on the head of the embryo across
the uterine wall.
Quantitative RT–PCR
Total RNA was isolated from mouse cerebral cortex and human brain tissue using
RNeasy-Plus Mini Kit according to the manufacturer’s protocol
(Qiagen). cDNA was synthesized using the Quantitect Reverse Transcription Kit,
according to the manufacturer’s protocol (Qiagen). Quantitative
real-time RT-PCR experiments were performed using oligonucleotides specific for
mouse hypoxanthine phosphoribosyltransferase 1 and cyclophilin-A; human
β-actin and GAPDH, and mouse and humanNMDAR subunits genes
(oligonucleotide sequences are shown in Supplementary Table 5). Amplification was done using SYBR-Green and Chemistry (Roche
Diagnostics) and Roche amplification technology (Light Cycler
480). All experiments were performed in duplicate or triplicate. To avoid any
bias, all samples were blinded before analysis. Only after the final samples
were analysed and described, the samples were genotyped. Human fetal brain and
adult cerebral cortex mRNAs, used as controls, were purchased from BD
Biosciences Clontech (Palo Alto, CA, USA).
Animal slice preparation
Tsc1 and Tsc1mice
(P14–P16) were anaesthetized with ether and killed by decapitation in agreement with the
European Directive 86/609/EEC requirements.The brain was rapidly removed and placed in an oxygenated ice-cold saline buffer.
Transverse 300-μm-thick coronal slices were cut using a vibratome
(Leica VT1000S; Leica Microsystems Inc., Deerfield, IL, USA) in ice-cold
protecting solution oxygenated with 95% O2 and 5% of CO2.
Before recording, slices were incubated in an artificial cerebrospinal fluid
(ACSF-1) solution containing (in mM): 125 NaCl, 3.5 KCl, 1 CaCl2, 2 MgCl2, 1.25 NaH2PO4, 26
NaHCO3 and 10
glucose, equilibrated at
pH 7.3 with 95% O2 and 5% CO2 at room temperature
(22–25 °C) for at least 1 h to allow
recovery. For the recordings, we used ACSF of the same composition but with
2 mM of CaCl2 and 1 mM of MgCl2 (ASCF-2).
Immunostaining procedures
For immunostaining, P14–P16mouse brains were perfused with
Anti-genfix solution and sliced at 100 μm on a vibratome
(Microm). Slices were blocked at room temperature for 1 h with 5%
normal goat serum (NGS) and 0.3% Triton X-100 in phosphate-buffered saline (PBS)
and incubated overnight at 37 °C with the upper cortical
layer marker CDP/CUX1 (M-222 Santa Cruz Biotechnology; 1/200).
Human cortical slice preparation
After surgical resection, the cortical tissue was placed within 30 s
in ice-cold oxygenated protecting solution that contained in (mM): 110
choline chloride, 26
NaHCO3, 10
D-glucose, 11.6
sodium ascorbate, 7
MgCl2, 3.1
sodium pyruvate, 2.5
KCl, 1.25 NaH2PO4 and 0.5
CaCl2,
300 mOsm and transported to the neurophysiology laboratory, within
<5 min. Cortical slices
(400–900 μm) were prepared in the same solution,
and were then transferred to holding chambers in which they were stored at room
temperature (20–22 °C) in ACSF-1. Recordings were
performed in ACSF-2.
Electrophysiological recordings from brain slices
Slices were transferred to the recording chamber and perfused with oxygenated
recording ACSF-2 at
3 ml min. Neurons
were visualized using infrared differential interference contrast microscopy.
Whole-cell patch-clamp recordings were performed at room temperature by using
either an EPC-9 amplifier and Patch Master
software (HEKA Elektronik, Germany) or
Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA, USA) and custom-made
software based on IgorPro and filtered at 3–10 kHz. Patch
pipettes were pulled from borosilicate glass capillaries (World Precision
Instruments, Sarasota, USA) and had resistances of
4–6.5 MΩ when filled with the internal solution
of the following composition (in mM): 130 K-gluconate, 10 Na-gluconate, 4 NaCl, 4 MgATP, 4 phosphocreatine, 10 HEPES and 0.3 GTP (pH 7.3 with KOH). Biocytin (final concentration 0.3–0.5%) was added
to the pipette solution to label the neurons from which recordings were
obtained.The series resistance estimated from the amplitude of the initial capacitive
transient in response to a 5-mV pulse was
8–24 MΩ. It was not compensated and was
monitored during each experiment. Experiments were terminated if the series
resistance changed by >15%. Spontaneous EPSCs were recorded for
15 min at −80 mV (the reversal potential for
GABAergic currents) and at −50 mV (potential at which the
block of NMDAR by magnesium is largely relieved). All recordings were made in
ACSF-2 without any proepileptic pharmacological drug. To minimize potential
sampling bias, the pups from at least three deliveries for each condition were
studied.
Analysis and statistics of in vitro data
The Mini Analysis 6.0.3 software (Synaptosoft Inc., Decatur, GA, USA) was used to analyse
the parameters of synaptic events. The threshold amplitude for detecting EPSCs
was set at twice the baseline noise (root mean square), and the EPSCs detected
by the software were visually inspected to minimize errors. Events that did not
show a typical synaptic waveform were rejected manually.For analysis, only events that did not show any signs of multiple peaks (that is,
contamination of rise or decay phases by subsequent events) were selected for
subsequent analysis of the kinetics and for exponential fitting.Averaged traces of sEPSC or mEPSC and cumulative probabilities of amplitude and
frequency for all cells were obtained using (Mini Analysis; Synaptosoft)
software and further analysed with Origin
software (MicroCal, Northampton, MA,
USA).For each neuron, original traces from individual experiments were aligned based
on the starts of their rising phases and averaged. These averaged traces from
individual experiments were averaged to form grand average traces.To quantify the current decay kinetics, we measured charge transfer of sEPSC
normalized by the peak amplitude. A larger charge transfer corresponds to slower
decay kinetics and vice versa. Normalized charge transfer was calculated by the
integrating the area under the current waveform in the interval of time between
peak of sEPSC and 300 ms after the peak for each individual cell
(Supplementary Fig. 14).In addition, to compare decay times between genotypes weighted time constant of
sEPSC or mEPSC decay (τw) were calculated using the
formula (equation 1):where I is the amplitude of the fast or slow component, and
τ is the respective decay time constant.Data are expressed as mean±s.e.m. All comparisons were two-tailed
t-tests or one-way ANOVA with post hoc Fisher’s
Least Significant Difference multiple comparison. Statistical significance for
cumulative probabilities was estimated using Kolmogorov–Smirnov and
Mann–Whitney tests. From three to nine animals were used for each
data set.
Immunocytochemistry
After the recording session, to visualize and identify the recorded neurons, we
visualized the biocytin
injected during whole-cell recordings. After 24 h in paraformaldehyde
(3%) at 4 °C, the sections were rinsed in PBS and
pre-incubated for 1 h in 0.3% Triton X-100 (Abcys) in PBS with 5% NGS
at room temperature. Slices were then incubated in Streptavidin-Cy3 (1:500) in
PBS Triton X-100 (0.3%) and NGS (5%) during 12 h at
4 °C. After thorough rinsing, slices were mounted in
fluoromount and coverslipped.
In vivo recordings and data analysis
Experiments were performed on postnatal days P9–P33 of inbred C57BL/6J
strain of both sexes of Tsc1 and
Tsc1mice from the same
litters issued from breading of Tsc1 females and
Tsc1 males. The
available littermates mice were randomly picked out of the cage and genotyped
after experiments. Surgery was performed under isoflurane anaesthesia. In brief, the
skull of the animal was cleaned of skin and periosteum. The skull was covered by
glue and dental cement except for a 4–9 mm2
window above the somatosensory cortex from one or two hemispheres. Two plastic
bars were fixed to the nasal and occipital bones of the pups head by dental
cement. After surgery, animals were warmed and were left for an hour for
recovery from anaesthesia. During recordings, the head was fixed to the frame of
the stereotaxic apparatus by attached bars; animals were surrounded by a cotton
nest and heated via a thermal pad (36.6–37.7 °C).
A silver chloride reference electrode was placed in the cerebellum or visual
cortex.EEG recordings were performed in non-anaesthetized head-restrained
Tsc1 and control
Tsc1mice. Sixteen
site-linear silicon probe (100 μm separation distance
between recording sites, Neuronexus Technologies, MI, USA) was placed into the
somatosensory cortex using the Paxinos and Franklin atlas (2001) at coordinates:
anterior–posterior=2–2.5 mm,
mediolateral=2–3 mm from Bregma,
1.2–1.5 mm depth, to trace the columnar activity at all
layers and CA1 zone of the hippocampus. Signals were amplified ( × 100)
and filtered at 3 kHz using a 16-channel amplifier (A-M systems,
Inc.), digitized at 10 kHz and saved to hard disk of PC using
Axoscope software (Molecular Devices). Recordings were analysed offline using
Clampfit and MATLAB software (The Mathworks, Natick, MA, USA).After the recordings, position of silicone probe was verified visually by DiI
staining of the electrode in 100 μm coronal sections from
fixed brain. The actions of UBP141 and DQP1105 were studied in vivo animal model of TSC in
keeping with recent guidelines for preclinical candidate drug evaluation67.We considered that multiunit activity occurred in epileptic discharges if they
appeared in a group of multiple spikes whose amplitude exceeded at least twice
the background activity within a period lasting for at least 20 s.
The first and last spikes of each discharge were used to define its onset and
termination, respectively. For each discharge, amplitude was defined as the
amplitude of the largest spike of the discharge. During EEG recordings, animals
were monitored visually to determine behavioural correlates of each
electrographic epileptic discharge.For EEG data analysis, raw data were preprocessed using a custom-developed suite
of programs in the MATLAB analysis environment. The wide-band signal was
downsampled to 1,000 Hz and used for local field potential (LFP)
signal. Positive polarity is graphed as up throughout the whole manuscript.LFPs were analysed by custom-written, MATLAB-based programs. Approximate
anatomical location of each recording site was estimated by physical depth
within the brain and corresponding age-matched histological assessment of
respective layers depth.Negative epileptic events were detected by the following steps: (1) the LFP
signal was band-pass filtered (5–100 Hz); (2) the times of
negative troughs with amplitude >5 s.d. from baseline level were detected
from filtered signal; and (3) aligned by the times of detected negative
epileptic events; the LFP segments from all channels were taken. Note that the
length of the segment is 200 ms with moment of negative trough at
0.CSD analysis across cortical depth was used to eliminate volume conduction and
localize synaptic currents. CSD was computed for each recording site according
to differential scheme for second derivative and smoothed with a triangular
kernel of length 3.
Preliminary screen for UBP141 and DQP1105 efficacy in vivo
Saline solution (200 μl), UBP141 (200 μl,
75 mg kg) and
DQP1105
(200 μl,
28 mg kg) were
injected i.p. Using in silico prediction of blood–brain
barrier permeation, we estimated expected concentration of compounds in the
brain. The decimal logarithm of brain to blood concentration ratio (logBB) and
drug concentration relationship in the brain and blood (plasma) tissues were
reconstructed using the Clark’s equation68 to assess
the logBB value for the UBP141 and DQP1105 compounds (equation (2)):where ClogP is a calculated octanol-water partitioning coefficient, and PSA is a
polar surface area (Supplementary Table
6 and Supplementary Fig.
15).Both parameters were determined from molecular fields using the VolSurf+
molecular modelling software programme (Molecular Discovery Ltd, Perugia,
Italy)69. According to this model the pharmacodynamic
distribution of the drugs in the brain after i.p. injection was assessed at
least as 6.7% and 15% of the initial concentration in blood for UBP141 and DQP1105, respectively.On the other hand, according to ref. 70, the
free-drug concentration in the peritoneal cavity is described as its exponential
decrease over distance (x) from the serosal surface (peritoneum) since
the drug diffuses down the concentration gradient into the bloodstream (Supplementary Fig. 16). At
characteristic diffusion length, × 0 (average distance travelled by
drug molecules), the concentration difference between tissue and blood is
decreased to 37% of its maximum value.Therefore, considering the decline of drug concentration at × 0 due to
peritoneal transport, and the logBB values the distribution of DQP1105 in the brain after i.p.
injection can be assessed. Assuming DQP1105 concentration in injected solution
(2.5 mM), volume of injection (200 μl) and total
circulating blood volume (of ~1,000 μl),
concentration in brain will be around 25 μM that is
entirely within the selectivity range for GluN2C/D (Supplementary Table 1). Similar estimation for UBP141 is complicated by the fact that
effect of UBP141 (in contrast
to DQP1105) was delayed for
40 min after i.p. injection, and unknown pharmacokinetic profile
could significantly influence the estimation.Preliminary screen for efficacy of UBP141 and DQP1105 was also performed directly to detect threshold for
antiepileptic activity. In 12 animals tested, i.p. injection of UBP141 with dosages of 19 or
57 mg kg did
not produce significant antiepileptic effects. In three animals tested, i.p.
injection of DQP1105 with a
dosage of 14 mg kg was
also ineffective. A dosage of
75 mg kg for
UBP141 and
28 mg kg for
DQP1105 were the lowest
effective doses identified by testing increasing doses of these compounds.
Multisite extracellular recordings from brain slices
Multisite extracellular recordings of spontaneous activity in slices were
performed at 30–32 °C using Multi-electrode array
(MEA) made up of 60 planar microelectrodes (TiN/SiN, 30 μm
electrode diameter, 200 μm pitch) arranged over an 8
× 8 square grid (Multi Channel Systems (MCS), Reutlingen, Germany).
Slices were maintained in dishes and perfused with oxygenated recording ACSF-2.
The spontaneous activity was monitored and recorded for
30–120 min, starting 15–20 min after
setting slice in the recording chamber at a stable level of activity. After
1,200 × amplification (MCS MEA 1060), signals were sampled at
10 kHz using the MCS data acquisition card controlled by the MCS
MCRack software. Data were analysed offline by using custom software tools
specifically developed in MATLAB .
Chemicals
All drugs were prepared as concentrated stock solutions
(10–100 mM), stored frozen and then thawed and diluted in
ACSF-2 immediately before use. Ro-25697 (αR,βS)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol
maleate, and DQP1105
5-(4-bromophenyl)-3-(1,2-dihydro-6-methyl-2-oxo-4-phenyl-3-quinolinyl)-4,5-dihydro-g-oxo-1H-pyrazole-1-butanoic
acid were purchased from Tocris Biosciences (Bristol, UK).
UBP 141
(2R*,3S*)-1-(phenanthrenyl-3-carbonyl)piperazine-2,3-dicarboxylic
acid was purchased from Abcam Biochemicals (UK). All other
chemicals used for electrophysiology were from Sigma.
Treatment with rapamycin
Rapamycin (ready-made solution, Sigma-Aldrich, USA,
2.5 mg ml in
DMSO
(2.74 mM)) was diluted with saline to a final concentration
0.125 mg ml−1 immediately
before use. The mice received single dose of rapamycin
(3 mg kg−1) by i.p.
injection (100 μl) or were injected by the equal volume of
vehicle once daily for 8 consecutive days. The electrophysiological recordings
were performed 24 h after the last administration.
Human subjects
Cortical tissue samples were obtained from three TSCepilepsypatients undergoing
surgery at the Departments of Pediatric Neurosurgery of Rothschild Foundation
(Paris) and Hopital La Timone (Marseille). Informed consent for the use of
postsurgical tissue for research purposes was obtained with protocols approved
by the Rothschild Foundation and Hopital La Timone review boards. Personal data
are stored into a specific database, which is declared to the La Commission
nationale de l'informatique et des libertés (CNIL). Bioethical
declaration procedure, related to conservation and preparation of human body
elements for scientific aims, was achieved during 2011 as referred to the
‘Collection NeurochirEpilepsie‘ under file number
DC-2011-1378, and has been approved by Le Comite de Protection des Personnes Ile
de France II and Ministère de l'enseignement supérieur et de
la recherche.The main clinical and neuropathological characteristics of the study population
are summarized in Supplementary Tables 3
and 4. TSC and FCD specimens were collected from patients who
underwent surgery for medically intractable epilepsy. All patients were
clinically diagnosed with TSC and FCD and presented a history of epilepsy.
Author contributions
N.L. and T.T. performed electrophysiological experiments and data analysis in brain
slices (patch-clamp); S.G., V.T., M.Min. and N.A.G. performed in vivo
experiments and data analysis; V.T. performed extracellular recordings and data
analysis in brain slices; A.B.—‘Double-hit model’
design and supervision; F.W., E.B. and S.G. performed electroporation and mutant
mice handling; E.P.-P. and C.C. performed quantitative RT-PCR; M.Milh., D.S., C.B.,
G.D., S.G. and O.De. performed TSCpatient’s phenotyping analysis,
surgery and clinical data collection; O.Du. and A.J.B. performed clinical and
neuropathological analyses supervision; S.G., F.W. and V.T. performed mice
genotyping; S.S. performed preliminary screen for drug efficacy; N.L., T.T., N.B.
and S.G. performed experiments and data analysis in human samples; N.B. was the
project leader; N.B., N.L., O.Du. and Y.B. performed experimental design; and N.B.,
N.L., O.Du., Y.B., A.R. and S.G. wrote the manuscript.
Additional information
How to cite this article: Lozovaya, N. et al. Selective suppression of
excessive GluN2C expression
rescues early epilepsy in a tuberous sclerosismurine model. Nat. Commun.
5:4563 doi: 10.1038/ncomms5563 (2014).
Authors: Timothy M Acker; Hongjie Yuan; Kasper B Hansen; Katie M Vance; Kevin K Ogden; Henrik S Jensen; Pieter B Burger; Praseeda Mullasseril; James P Snyder; Dennis C Liotta; Stephen F Traynelis Journal: Mol Pharmacol Date: 2011-08-01 Impact factor: 4.436
Authors: Marianna Baybis; Jia Yu; Allana Lee; Jeff A Golden; Howard Weiner; Guy McKhann; Eleonora Aronica; Peter B Crino Journal: Ann Neurol Date: 2004-10 Impact factor: 10.422
Authors: Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski Journal: J Neurosci Date: 2008-05-21 Impact factor: 6.167
Authors: Shu-Ichi Okamoto; Olga Prikhodko; Juan Pina-Crespo; Anthony Adame; Scott R McKercher; Laurence M Brill; Nobuki Nakanishi; Chang-Ki Oh; Tomohiro Nakamura; Eliezer Masliah; Stuart A Lipton Journal: Neurobiol Dis Date: 2019-03-27 Impact factor: 5.996
Authors: Elizabeth Hanson; Moritz Armbruster; Lauren A Lau; Mary E Sommer; Zin-Juan Klaft; Sharon A Swanger; Stephen F Traynelis; Stephen J Moss; Farzad Noubary; Jayashree Chadchankar; Chris G Dulla Journal: J Neurosci Date: 2019-03-07 Impact factor: 6.167
Authors: Sharon A Swanger; Katie M Vance; Timothy M Acker; Sommer S Zimmerman; John O DiRaddo; Scott J Myers; Christoffer Bundgaard; Cara A Mosley; Samantha L Summer; David S Menaldino; Henrik S Jensen; Dennis C Liotta; Stephen F Traynelis Journal: ACS Chem Neurosci Date: 2017-11-02 Impact factor: 4.418